Integrin Alpha 10 Antibody for CNS Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating glioblastoma and other malignant neoplasms in the central nervous system are inadequate, with limited effective detection and treatment options available, leading to poor patient outcomes due to the aggressiveness and heterogeneity of these tumors.
Innovation Solution
The development of methods and tools utilizing an antibody specifically binding to the integrin alpha 10 subunit for detection and treatment, including antibody-drug conjugates and nanoparticles, to target and inhibit tumor cells in the CNS, enabling precise diagnosis and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging studies and pathological exams are used for diagnosis, then detection capability is achieved, but the process is complex and time-consuming with no specific pre-surgical laboratory studies available
Solution Approach 1:
The patent extracts and focuses on a specific biomarker (integrin alpha 10 subunit) that is uniquely expressed in malignant CNS tumors but not in normal brain tissue or low-grade gliomas. This extraction of a single specific marker simplifies the diagnostic process from complex multi-modal imaging and pathology to a targeted immunohistochemical or in situ hybridization assay for ITGA10 expression
Solution Approach 2:
The patent introduces integrin alpha 10 subunit as an intermediary biomarker that mediates between the tumor cells and the detection method. This intermediary enables specific pre-surgical detection through laboratory studies, bridging the gap between conventional imaging and definitive pathological diagnosis
2Ease of operation
If standard treatment protocols are applied to all glioblastoma patients, then treatment uniformity is maintained, but individual tumor heterogeneity is not addressed leading to poor outcomes
Solution Approach 1:
The patent applies local quality by enabling differentiation of tumor subtypes through ITGA10 expression patterns. This allows treatment regimens to be tailored to specific tumor characteristics (high-grade vs low-grade, different molecular subtypes) rather than applying uniform treatment to all glioblastoma patients, addressing the heterogeneity issue while maintaining standardized protocols for each subtype
3Reliability
If no specific biomarker is used for detection, then all brain tumors must be diagnosed through invasive surgery and comprehensive imaging, but this leads to delayed diagnosis and increased patient risk
Solution Approach 1:
The patent enables preliminary action by providing a specific pre-surgical laboratory study (ITGA10 detection) that can be performed on biopsy samples before definitive surgical intervention. This preliminary detection of integrin alpha 10 subunit expression allows for earlier and more accurate diagnosis, reducing patient risk by avoiding unnecessary invasive procedures and enabling timely treatment planning
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of integrin alpha 10 subunit-specific antibodies and conjugates allows for targeted detection and treatment of malignant neoplasms, potentially improving survival rates and treatment outcomes by specifically identifying and addressing tumor cells in the CNS.
Implementation Method 1
an antibody specifically binding to an integrin alpha 10 subunit
Data Source
AI summary
The present invention concerns methods of diagnosing and treating a malignant neoplasm of the CNS by detecting mammalian tissue expressing integrin alpha 10 subunit or a fragment or variant thereof, and administering a drug specific for integrin alpha 10 subunit.